Merz Pharma Group has acquired the Swiss cosmetics, over-the-counter and prescription skincare business Neocutis for an undisclosed sum.
The German pharmaceutical firm said the deal would strengthen its aesthetics business and particularly its US business.
‘Neocutis is an innovative company with an excellent presence in the US market, and a promising potential for development,’ said Philip Burchard, CEO of Merz Pharma Group.
The acquisition, which closed on 22 July, will be managed in North America by Merz Pharma Group’s US affiliate, Merz North America, which will also integrate marketing of Neocutis’ precription skincare products in the US.
Neocutis is an innovative company with an excellent presence in the US market, and a promising potential for development
‘Neocutis’ line of topical skin care products complements our current portfolio of aesthetic injectable products and expands our ability to provide patients and physicians with innovative, high-quality aesthetic products along the full continuum of care,’ said Bill Humphries, President and CEO of Merz North America.
‘We are proud to contribute to Merz’s global leadership in aesthetic and medical dermatology, and we remain committed to growing the US business via both organic growth and additional licensing and acquisition opportunities.’
Merz North America offers a range of products for minimally invasive treatments, including the dermal fillers Radiesse Volumizing Filler and Belotero Balance, the neurotoxin Xeomin, the Mederma family of products for scar care and stretch marks therapy and an injectable product for the treatment of varicose veins.
Neocutis was founded in February 2003 as a spin-off from the medical faculty of the Lausanne University Clinic, Switzerland. The privately owned company is headquartered in Lausanne, Switzerland and develops and distributes cosmetic products for dermatologic conditions and anti-ageing skincare. The company entered the US market in 2009 and since then has seen double-digit growth annually.
